6-氯-2-(三氟甲基)烟腈 | 1245913-20-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 6-氯-2-(三氟甲基)烟腈
• 英文名称: 6-Chloro-2-(trifluoromethyl)nicotinonitrile
• 英文别名: 6-chloro-2-(trifluoromethyl)pyridine-3-carbonitrile
• CAS: 1245913-20-5
• 化学式: C₇H₂ClF₃N₂
• 分子量: 206.55
• InChiKey: YNOOOWSRQHMRAA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  36.7
• 氢给体数：
  0
• 氢受体数：
  5

安全信息

• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335

文献信息

• FXR (NR1H4) MODULATING COMPOUNDS
  申请人：Gilead Sciences, Inc.

  公开号：US20170355693A1

  公开（公告）日：2017-12-14

  The present disclosure relates generally to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.

  本公开涉及一般与结合NR1H4受体（FXR）并作为FXR激动剂的化合物有关。本公开进一步涉及利用这些化合物制备药物，用于通过这些化合物结合所述核受体治疗疾病和/或病况，以及用于合成这些化合物的过程。
• AZETIDINE DERIVATIVES AS FXR (NR1H4) MODULATORS
  申请人：Gilead Sciences, Inc.

  公开号：EP3730487A1

  公开（公告）日：2020-10-28

  The present disclosure relates generally to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.

  本公开一般涉及与 NR1H4 受体 (FXR) 结合并作为 FXR 激动剂的化合物。本公开进一步涉及化合物在制备通过所述化合物结合所述核受体治疗疾病和/或病症的药物中的用途，以及所述化合物的合成工艺。
• FXR (NR1H4) modulating compounds
  申请人：Gilead Sciences, Inc.

  公开号：US10329286B2

  公开（公告）日：2019-06-25

  The present disclosure relates generally to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.

  本公开一般涉及与 NR1H4 受体 (FXR) 结合并作为 FXR 激动剂的化合物。 本公开进一步涉及化合物在制备通过所述化合物结合所述核受体治疗疾病和/或病症的药物中的用途，以及所述化合物的合成工艺。
• [EN] FXR (NR1H4) MODULATING COMPOUNDS<br/>[FR] COMPOSÉS MODULANT LE FXR (NR1H4)
  申请人：GILEAD SCIENCES INC

  公开号：WO2017218337A1

  公开（公告）日：2017-12-21

  The present disclosure relates generally to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.